NCT05607043 is a NA clinical trial of Testing for SARS CoV2 RNA in SARS-CoV2 Infection, sponsored by Rutgers, The State University of New Jersey.

Who is sponsoring NCT05607043?

NCT05607043 is sponsored by Rutgers, The State University of New Jersey.

What drugs are being tested in NCT05607043?

Interventions in NCT05607043: Testing for SARS CoV2 RNA.

What condition does NCT05607043 study?

NCT05607043 studies SARS-CoV2 Infection.

Is NCT05607043 still recruiting?

NCT05607043 is currently completed. Last updated 22 September 2023.

Are results published for NCT05607043?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-09-22 · How we verify

NCT05607043

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rutgers Pilot for PREDICT- Patient LAB Test

Completed NA Results posted Last updated 22 September 2023

What this trial tests

NA trial testing Testing for SARS CoV2 RNA in SARS-CoV2 Infection in 11 participants. Completed in 25 February 2021.

Timeline

31 January 2021

Primary endpoint
25 February 2021

25 February 2021

Quick facts

Lead sponsor	Rutgers, The State University of New Jersey
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	11
Start date	31 January 2021
Primary completion	25 February 2021
Estimated completion	25 February 2021
Sites	1 location across United States

Drugs / interventions tested

Testing for SARS CoV2 RNA

Conditions studied

SARS-CoV2 Infection — all drugs for SARS-CoV2 Infection →

Sponsor

Rutgers, The State University of New Jersey

Who can join

Adults 18 to 99, any sex, with SARS-CoV2 Infection. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Patient Willingness to Participate in the Study Primary · Day 1

Percentage of 36 patients who were approached to enroll in the study who actually enrolled

Group	Value	95% CI
SARS-CoV-2 Testing	30

Willingness/Ability to Follow Through With the Study With Surveys, Triage and Testing Primary · 26 days

Percentage of patients who complete the study

Group	Value	95% CI
SARS-CoV-2 Testing	9

Patient Test Completion Primary · Day 1

Percentage of patients with completed SARS-CoV-2 testing

Group	Value	95% CI
SARS-CoV-2 Testing	10

Percentage of Subjects Who Complete Study Activities to Optimize Gap Between Testing and Study Visit Primary · From initial consent through study completion- approximately 4 weeks

Percentage of subjects completing study activities within the defined optimal window

Group	Value	95% CI
SARS-CoV-2 Testing	9

Ease of Complying With Protocol Primary · Day 26

Number of participants indicating that it was easy to complete the surveys

Group	Value	95% CI
SARS-CoV-2 Testing	8

Percent of Patients Who Completed All of the Required Surveys Primary · 1 week

Percentage of patients participating in the study who completed pre-visit, triage and post-visit surveys

Group	Value	95% CI
SARS-CoV-2 Testing	9

Sponsor's own description

A pilot study was initiated to assess feasibility of testing asymptomatic dental patients presenting to the Oral Medicine Clinic at Rutgers School of Dental Medicine for SARS-CoV-2 viral RNA using an FDA approved RT-PCR test for SARS-CoV2- an RNA RT-PCR assay (Accurate Diagnostics)

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for SARS-CoV2 Infection

Currently open trials in the same condition.

NCT05852873 — PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway · Phase 3 · active not recruiting
NCT04910269 — Outpatient Treatment With Anti-Coronavirus Immunoglobulin · Phase 3 · recruiting
NCT04830852 — Pediatric COVID Outcomes Study (PECOS) · active not recruiting
NCT04844242 — MISC COVID-19 Study in Pediatric Population · recruiting

Other Rutgers, The State University of New Jersey trials

Trials by the same sponsor.

NCT07243886 — Mobile-based Obstetric Monitoring for Pregnancies Complicated by Hypertension and/or Diabetes (MOM-HD) · NA · not yet recruiting
NCT06955130 — Lactate and Glycerol Contribution to Gluconeogenesis · NA · not yet recruiting
NCT06822010 — SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma · Phase 2 · not yet recruiting
NCT07525011 — Comparative Study of Denture Fabrication Techniques · NA · not yet recruiting
NCT06834204 — Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05607043 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rutgers, The State University of New Jersey
Last refreshed: 22 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05607043.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing